Sapient Capital LLC Makes New Investment in Cardinal Health, Inc. $CAH

Sapient Capital LLC bought a new position in Cardinal Health, Inc. (NYSE:CAH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,529 shares of the company’s stock, valued at approximately $534,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CAH. Norges Bank bought a new position in Cardinal Health in the 4th quarter valued at approximately $790,344,000. Wellington Management Group LLP grew its stake in shares of Cardinal Health by 153.2% during the third quarter. Wellington Management Group LLP now owns 5,804,090 shares of the company’s stock worth $911,010,000 after buying an additional 3,511,579 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Cardinal Health by 1,328.1% during the fourth quarter. Marshall Wace LLP now owns 951,259 shares of the company’s stock worth $195,484,000 after buying an additional 884,648 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Cardinal Health by 7,053.4% during the first quarter. Bessemer Group Inc. now owns 750,038 shares of the company’s stock worth $158,491,000 after buying an additional 739,553 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Cardinal Health by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 31,441,258 shares of the company’s stock worth $6,461,179,000 after buying an additional 617,775 shares in the last quarter. 87.17% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CAH shares. Zacks Research downgraded Cardinal Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 12th. Robert W. Baird set a $248.00 target price on Cardinal Health in a report on Friday, May 1st. Wells Fargo & Company dropped their target price on Cardinal Health from $256.00 to $245.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Morgan Stanley lifted their price target on Cardinal Health from $245.00 to $255.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Cardinal Health from $243.00 to $215.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Fifteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.73.

Cardinal Health Trading Down 1.0%

Shares of Cardinal Health stock opened at $233.32 on Wednesday. The business has a 50-day moving average price of $224.29 and a two-hundred day moving average price of $215.72. Cardinal Health, Inc. has a 1-year low of $137.75 and a 1-year high of $243.21. The company has a market cap of $54.65 billion, a P/E ratio of 35.68, a PEG ratio of 1.15 and a beta of 0.49.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.